Hovione executives Jean-Luc Herbeaux and Guy Villax stand in front of their booth at CPhI in Milan (Hovione PR)
March 3, 2022 12:38 PM EST
Manufacturing

Af­ter 25 years, Hov­ione's CEO will step down; Helsinn gains in­fi­gra­tinib li­cense from Bridge­Bio 

Josh Sullivan

Hov­ione’s cur­rent COO will be­come its CEO on April 1.

The com­pa­ny an­nounced that Guy Vil­lax, the CEO for 25 years …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times